How should a patient with suspected Guillain‑Barré syndrome be managed?

Management of Suspected Guillain-Barré Syndrome

Initiate intravenous immunoglobulin (IVIg) at 0.4 g/kg daily for 5 days in patients unable to walk unaided within 2 weeks of weakness onset, while simultaneously monitoring for respiratory failure using the Erasmus GBS Respiratory Insufficiency Score (EGRIS). 1, 2

Immediate Recognition and Diagnosis

Suspect GBS when you observe:

• Rapidly progressive bilateral weakness starting in legs and ascending to arms/cranial muscles over days to 2 weeks
• Areflexia or hyporeflexia (present in almost all patients at nadir)
• Distal paresthesias preceding or accompanying weakness
• Recent infection history (within 6 weeks in two-thirds of patients)

Critical timing consideration: If maximum disability occurs within 24 hours or after 4 weeks, strongly consider alternative diagnoses 1.

Atypical Presentations Requiring High Index of Suspicion

In children under 6 years, watch for:

• Refusal to bear weight
• Poorly localized pain
• Irritability or meningism
• Unsteady gait without obvious weakness 1

Important caveat: Pure motor variants with acute motor axonal neuropathy (AMAN) subtype may have normal or exaggerated reflexes throughout the disease course 1.

Step 1: Determine Need for ICU Admission

Admit to ICU immediately if any of the following are present 1:

• Clinical signs of respiratory distress (breathlessness at rest/talking, inability to count to 15 in one breath, accessory muscle use)
• Vital capacity <15-20 ml/kg or <1 liter
• Severe autonomic dysfunction (arrhythmias, marked blood pressure variation)
• Severe bulbar weakness or diminished cough reflex
• Rapid progression of weakness

Risk Stratification for Mechanical Ventilation

Calculate EGRIS score on admission to predict probability (1-90%) of requiring ventilation within 1 week 1:

EGRIS Components:

• Days from weakness onset to admission (≤3 days = 2 points; 4-7 days = 1 point)
• Facial/bulbar weakness present = 1 point
• MRC sum score (≤20 = 4 points; 21-30 = 3 points; 31-40 = 2 points; 41-50 = 1 point)

Risk factors for prolonged ventilation warranting early tracheostomy consideration 1:

• Inability to lift arms from bed at 1 week post-intubation
• Axonal subtype or unexcitable nerves on electrophysiology

Step 2: Initiate Definitive Treatment

First-Line Treatment Options (Equally Effective)

IVIg is preferred over plasma exchange due to easier administration and wider availability 1, 2:

IVIg Regimen: 0.4 g/kg body weight daily for 5 consecutive days (total 2 g/kg)

• Recommend within 2 weeks of weakness onset if unable to walk unaided 2
• Consider as good practice point between 2-4 weeks 2

Plasma Exchange Alternative: 200-250 ml plasma/kg body weight over 5 sessions (12-15 L total over 1-2 weeks)

• Use within 4 weeks of weakness onset if unable to walk unaided 2
• More likely to be discontinued due to adverse events 1

Critical Treatment Pitfalls to Avoid

Do NOT use 1, 2:

• Corticosteroids (oral corticosteroids shown to have negative effect on outcome)
• Sequential plasma exchange followed by IVIg (no more effective than either alone)
• Second course of IVIg in patients with poor prognosis (not recommended)

Special Population Considerations

Pregnant women: IVIg preferred over plasma exchange (neither contraindicated, but plasma exchange requires additional monitoring) 1

Children:

• Use standard adult IVIg regimen (0.4 g/kg × 5 days) rather than 2-day regimen
• Important: 2-day regimen associated with higher treatment-related fluctuation rates (5/23 vs 0 patients) 1

Miller Fisher Syndrome (MFS):

• Treatment generally not recommended for pure MFS (most recover completely within 6 months without treatment)
• However, monitor closely as subgroup can develop limb weakness, bulbar palsy, or respiratory failure 1

Bickerstaff Brainstem Encephalitis (BBE): Treat with IVIg or plasma exchange despite limited evidence 1

Step 3: Supportive Care and Monitoring

Dysautonomia Management

Monitor for common autonomic complications 1:

• Blood pressure/heart rate instability
• Pupillary dysfunction
• Bowel/bladder dysfunction

Pain Management

Weakly recommend for neuropathic/radicular/muscular pain 2:

• Gabapentinoids
• Tricyclic antidepressants
• Carbamazepine

Note: No specific treatment recommended for fatigue 2

Step 4: Prognostication

Calculate modified Erasmus GBS Outcome Score (mEGOS) on admission to predict functional outcome at 3 months and beyond 1, 2, 3.

Key prognostic points 1:

• Recovery can continue beyond 3 years after onset
• Recurrence is rare (2-5%)
• If progression continues after 8 weeks from onset, consider changing diagnosis to acute-onset CIDP (occurs in ~5% of initial GBS diagnoses) 2

Diagnostic Confirmation (Parallel to Treatment)

While initiating treatment, obtain:

• CSF examination: Valuable when diagnosis uncertain 2
• Electrodiagnostic testing: Supports diagnosis but does not reliably predict subtype 2, 4
• Anti-GQ1b antibodies: Only when MFS suspected 2
• Nodal-paranodal antibodies: When autoimmune nodopathy suspected 2
• MRI or ultrasound of peripheral nerves: Consider in atypical cases (enlarged cervical nerve roots indicate early spinal root inflammation) 1

Anti-ganglioside antibody testing has limited clinical value in typical motor-sensory GBS 2.